Shilpa Medicare Limited — Important, 10-01-2025: General Updates

Shilpa Medicare Limited has received Marketing Authorization from Portugal for its Tadalafil Orodispersible Films, 20 mg. This positions Shilpa as the first global entity to secure approval for this convenient oral dosage form, which is designed for the treatment of erectile dysfunction in adult males. The European market for oral Tadalafil formulations is estimated at approximately USD 400 million. This approval is a significant milestone, coming from its finished dosage form manufacturing facility in Dabaspet, Bengaluru, which is already accredited by MHRA UK. The facility continues to ensure compliance with quality standards as it expands its product offerings in European and UK regulated markets, presenting a positive outlook for growth and market penetration.